Abstract

In the recent years immunotherapy has gained important role in cancer management. Immunostimulating effects of thymus-derived peptides on carcinogenesis have been actively studied in both animals and humans. Gc protein derived macrophage-activating factor (GcMAF) was found to have potent effect on macrophage phagocytic activity. Immunostimulating effects of GcMAF and peptides of thymus can be effectively combined together and with other treatment modalities of cancer. The current case report demonstrates outcomes of combination of GcMAF Forte and HT Thymus (peptides of thymus) in the management of metastatic colorectal adenocarcinoma. This case study suggests that individually prescribed immunotherapy can be a promising alternative in management of advance forms of cancer, especially when options of treatment are limited.

Highlights

  • Liver is the most common site of metastasizing of colorectal cancer

  • Metastatic liver lesions are commonly encountered in colorectal cancers and contribute to increased mortality in this group of patients [1]

  • In spite of surgical resection in combination with chemotherapy being considered as a golden standard of treatment, such approach has its limitations

Read more

Summary

Introduction

Liver is the most common site of metastasizing of colorectal cancer. Secondaries in liver are found in 25-35% of patients going for surgery of primary colorectal tumors [1]. When returned for the follow up patient presented with pain in the right hypochondrial region with a palpable mass in that area, fatigue, loss of appetite, deranged liver function test due to increased levels of transaminases, gamma-glutamyltransferase. As a complementary diagnostic tool, prior to commencement of immunotherapy radio-thermometry was done, findings of which corresponded to the findings of the CT scan: measurements showed increased internal temperature in the areas of liver lesions by 2-3 degrees. Two months after the commencement of the immunotherapy with GcMAF Forte with HMW-HA (LabRMS Therapeutics Ltd) and HT Thymus (MF Plus Ltd) patient had a dramatic improvement of clinical symptoms, such as pain, fatigue and loss of appetite. After the completion of initial course of treatment with GcMAF Forte and HT Thymus liver function test has completely normalized, serum carcinoembryonic antigen (CEA) level reduced and radiothermometry showed reduction of temperature in the areas of liver lesions. There were no side-effects from the treatment with GcMAF Forte and HT Thymus

Discussion
Disclosure
Findings
Conflict of Interests
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call